HBI-2438
Phase 1Small molecule
HBI-2438 is one of 49 small molecule programs targeting Patients With Solid Tumors. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
68 competitors in Patients With Solid Tumors
#DrugCompanyPhaseTrials
1Taxotere
AAvyxa
Phase 3
Faslodex
FFresenius Kabi USA, LLC
Phase 3
Keytruda
Merck & Co.Phase 2
Avastin
RochePhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Imfinzi
AstraZenecaPhase 2
Eloxatin
TevaPhase 2
Lynparza
AstraZenecaPhase 2
Mektovi
PfizerPhase 2
Pemazyre
IncytePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HBI-2438. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- HHUYABIO International, LLC.